Vifor Pharma AG Logo

Vifor Pharma AG

Global leader in therapies for iron deficiency, anemia, and kidney disease.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen

Description

Vifor Pharma AG, now operating as CSL Vifor, is a global pharmaceutical company that develops, manufactures, and markets products for severe and chronic diseases. It is a global leader in therapies for iron deficiency and iron deficiency anemia, with applications in heart failure, kidney disease, gastroenterology, and women's health. The company also has a strong and growing presence in nephrology, aiming to address the full spectrum of kidney disease through its joint company with Fresenius Medical Care Renal Pharma. Vifor Pharma's business model includes strategic global partnering, in-licensing, and the development of innovative therapies to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Advicenne Logo
A specialty pharmaceutical company developing treatments for rare renal diseases.
France
ALDVI
AegirBio AB Logo
A diagnostics company specializing in therapeutic drug monitoring for biological drugs.
Sweden
AEGIR
Aelis Farma Logo
Biopharmaceutical company developing CB1 receptor inhibitors for CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Clinical-stage company developing therapeutic applications for botulinum toxins.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics with integrated R&D and manufacturing.
Japan
2927
AGENUS INC Logo
A clinical-stage biotechnology company specializing in immuno-oncology therapies.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Biopharmaceutical company developing therapies for rare and genetically defined diseases.
United States of America
AGIO
AHN-GOOK PHARMACEUTICAL Co., Ltd. Logo
Develops and markets medicines, focusing on respiratory and cardiovascular treatments.
South Korea
001540
Akari Therapeutics Plc Logo
Develops next-gen antibody-drug conjugates using proprietary cancer-killing toxins.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
A biopharmaceutical company that develops and commercializes therapeutics for kidney disease.
United States of America
AKBA

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.